|Day Low/High||2.16 / 2.27|
|52 Wk Low/High||1.99 / 5.05|
Here’s when we would consider adding to Aurora Cannabis.
Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Amid volatile market activity, we added to four positions last week.
We are buying more shares of AcelRx Pharmaceuticals following an FDA advisory committee’s approval of its NDA candidate.
The majority of our positions outperformed our benchmark during a challenging week for the stock market.
In trading on Monday, shares of AcelRx Pharmaceuticals Inc touched a new 52-week high of $5.03/share. That's a 224.52% rise, or $3.48 per share from the 52-week low of $1.55 set back on 10/19/2017.
FDA review of AcelRx Pharma's DSUVIA should produce a significant reaction in the shares.
We initiated a new position and added to a newer name during a mixed week for the portfolio.
There are several reasons to believe in AcelRx Pharmaceuticals’ recent rise.
Last week was a frenetic one for the portfolio as we scaled into one name, added another to the fold, and booked some hefty profits in a cannabis stock.
Last week we re-initiated a position in Aurora Cannabis, exited USA Technologies and added to our holdings in Del Frisco's Restaurant Group.
We added a starter a position in Parateum Corp. during a challenging week for the portfolio.
We added 2 new positions last week as the portfolio finished the summer strong.
Last week was a busy one for the portfolio as we exited 3 positions.
There were several bright spots in the portfolio last week, including Habit Restaurants and USA Technologies.
The portfolio had several big winners last week as shares of Habit Restaurants and Energy Recovery soared.
While ArcelRx Pharmaceuticals faces key milestones, I'm excited about Energy Recovery.
We trimmed one position and added to another last week as smaller-cap stocks took a hit.
During a week that showed little change for the major stock market indices, the portfolio had a number of outperformers.
Similar to the Russell 2000 trading off last week so too did a number of our holdings, although there were bright spots as well.
Winning position AcelRx recently announced a public offering.
It was a challenging week for the portfolio amid continued trade and tariff concerns.
It was a good week for the portfolio, as a large majority of positions outperformed the market.
Last week, we initiated a position in Farmland Partners and trimmed our holdings in AcelRx Pharmaceuticals.
We will sell some of our AcelRx holdings as the stock moves through out current price target.
We still like all of these names after developments this week.
During the week we scaled into two existing positions and added back shares of a former holding.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.